CClinicalTrials.gg
CompletedNCT07669714DAIRUpdated Jul 7, 2026

Comparison of Debridement, Antibiotic, Implant Retention and Implant Exchange in Early-stage Fracture-related Infections

An observational study in Orthopedic Surgery, Fracture Related Infection and Debridement, sponsored by Antalya Health Sciences University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Antalya Health Sciences University · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
94
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare the clinical outcomes of debridement, antibiotics, and implant retention (DAIR) and implant removal/replacement methods used in the treatment of fracture-related infections, and to determine the infection-free fracture healing rates and the factors affecting treatment success.

Read the detailed description

Fracture-related infection remains one of the most challenging musculoskeletal complications in orthopedic trauma surgery. Its diagnosis is a multi-stage process based on various diagnostic criteria. The international consensus definition of fracture-related infection was standardized in 2018, and this definition has been reinforced with updates in subsequent years. The recently validated consensus definition of fracture-related infection offers clinicians the opportunity to standardize clinical reports and improve the quality of published literature. The consensus definition definitively indicates the presence of infection [confirmatory criteria; (1) fistula/sinus tract/incision site dehiscence, (2) purulent drainage during surgery, (3) growth of the same pathogen in ≥2 separate deep tissue/implant cultures] or possibly indicates the presence of infection [suggestive criteria; The diagnostic criteria are based on (1) local pain, redness, increased heat, (2) wound exudation, (3) fever, (4) elevated CRP and ESR, (5) implant loosening, osteolysis, non-union. The presence of suggestive criteria should raise suspicion of infection, and further investigation should be conducted. The presence of at least one confirmatory sign is associated with high diagnostic performance and is pathognomonic for the presence of fracture-related infection. This definition also guides the treatment of fracture-related infections. Fracture-related infections are a significant complication causing high morbidity in orthopedic trauma surgery. This study aims to compare the clinical outcomes of DAIR and implant removal/replacement methods used in the treatment of fracture-related infections, and to determine the infection-free fracture healing rates and the factors affecting treatment success.

02

Conditions studied

  • Orthopedic Surgery
  • Fracture Related Infection
  • Debridement
  • Implant Retention
  • Implant Removal/Replacement

Keywords

  • orthopedic surgery
  • fracture-related infection
  • debridement
  • implant retention
  • implant removal/replacement
03

In context

Lead sponsor

Antalya Health Sciences University is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study planned to include over 18 years old patients who underwent internal fixation after fracture, had a fistula and/or sinus tract, or purulent drainage with incision dehiscence, at least 2 positive deep tissue cultures or at least 3 positive soft tissue cultures, whose findings started early (6 weeks), and who underwent DAIR or implant removal/replacement due to fracture-related infection.

Inclusion criteria

  • internal fixation after fracture
  • presence of fistula and/or sinus tract or purulent drainage with dehiscence at the incision site
  • at least 2 positive deep tissue cultures or at least 3 positive soft tissue cultures
  • early onset of symptoms (6 weeks)
  • DAIR or implant removal/replacement due to fracture-related infection

Exclusion criteria

Exclusion Criteria:

  • Under 18 years old patients
  • prosthetic joint infection
  • only conservative treatment applied
  • pathological fracture due to primary bone tumor
  • simultaneous infection foci in the same extremity
  • fracture-related infection not confirmed by international consensus criteria
  • poor reduction after internal fixation
  • inappropriate or inadequate internal fixation
  • radiological images less than 1 year old
  • findings starting late (after 6 weeks)
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
94 participants (actual)
Patient registry
No

Groups and cohorts

  • DAIR

    Other: DAIR

  • Implant removal/replacement

    Other: Implant removal/replacement

Interventions

  • OtherDAIR

    DAIR: Debridement, antibiotic retention and implant removal

  • OtherImplant removal/replacement

    implant removal/replacement

06

What researchers measure

Primary outcomes

  1. Fracture healing rates

    Infection-free fracture healing rates

    Time frame: 1 year

Secondary outcomes

  1. Recurrence rate

    Infection recurrence rate

    Time frame: 1 year

  2. Union time

    Time to union

    Time frame: 1 year

07

Study locations

1 site
  • University of Health Sciences, Antalya Training and Research Hospital
    Antalya, Turkey (Türkiye)
08

References and documents

Publications

  • Cury GCT, Guidoni PB, Ikeda LH, Ferreira CCUAC, Goncalves MAM, Leonhardt MC, Lima ALM, Dos Santos Silva J, Kojima KE. Outcomes of DAIR for early fracture related infection: Clinical remission, recurrence, and bone healing in a retrospective cohort. Injury. 2025 Nov;56(11):112749. doi: 10.1016/j.injury.2025.112749. Epub 2025 Sep 5. PubMed 40945224 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07669714
Lead sponsor
Antalya Health Sciences University
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Apr 16, 2026
Primary completion
Jun 23, 2026
Completion
Jul 1, 2026
Last update
Jul 7, 2026

Study contacts

Melih Unal
principal investigator · University of Health Sciences, Antalya Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion